Introducing NXtec Hereditary Cancer Panel 2 – a broad panel for the detection of CNVs in cancer-associated genes and the presence of selected variants.
Exciting news about our digitalMLPA portfolio – two new digitalMLPA™ assays will be launched soon: NXtec™ D002 Hereditary Cancer Panel 2 and NXtec™ D024 KaryoProfiler!
Effective from 1 January 2026, we will be implementing a price increase of 3.6% on average on most of our products.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline.
Introducing NXtec Hereditary Cancer Panel 2 – a broad panel for the detection of CNVs in cancer-associated genes and the presence of selected variants.
P242 Pancreatitis just received a major update, with the recently released D1 version featuring nine new target probes and three new mutation-specific probes, as well as three replaced target probes and eight replaced reference probes. The updated probe content facilitates enhanced detection of HP-related genetic alterations and improves assay robustness.
Join our mailing list to receive the latest information about our products, technologies and website.